SIS 302 AA
Alternative Names: SIS-302-AALatest Information Update: 01 Dec 2023
At a glance
- Originator SiSaf
- Developer SiSaf; Undetermined
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alopecia areata
Most Recent Events
- 11 Oct 2023 Phase-II clinical trials in Alopecia areata (unspecified route), prior to October 2023 (SiSaf pipeline, October 2023)